Pharmacists to Descend on Washington
Pharmacists to Descend on WashingtonDIR fees and health-care reform will lead pharmacists’ legislative concerns.
Pharmacists Pushing for DIR Relief
Pharmacists Pushing for DIR ReliefCommunity pharmacists fight against financial pressure for their survival.
The largest cause of medical errors is congressThere has been much published in both the medical and lay press about the magnitude of errors in medicine. This is a contentious subject with wildly variable results most likely due to the difficulties associated with the many and varied complexities of clinical medicine.
Health Care a Central Issue in President Trump’s Speech to CongressIn his address to Congress, Trump hinted at what could be in the future for healthcare reform.
The Top Six Ways Trump’s Policies Will Impact Pharmacies
The Top Six Ways Trump’s Policies Will Impact PharmaciesHow the new Trump administration will affect everything from the ACA to the FDA.
Republicans face difficult post-election healthcare decisionsACA repeal/replace was a Congressional Republican cornerstone, so there will be lots of pressure to move quickly. But that may be easier said than done.
Divided Congress comes together to fight opioid abuseoctors groups are applauding newly-approved national legislation to fight opioid abuse while calling for more funds to implement many of the bill’s programs. The Comprehensive Addiction and Recovery Act of 2016 (CARA) passed both houses of Congress in July after Democrats backed off their demands that higher levels of funding be included in the bill.
Presidential candidates’ ACA plansHere’s a closer look at what the presidential candidates vow to do if elected to the Oval Office.
The last word: Will 21st Century Cures Act harm patient safety?In "The Last Word," John N. Frank talks about the future of the 21st Century Cures Act and how it could lead to an increase of medications in the marketplace.
Hepatitis C drugs come under fire againA new US Congressional report about the price of hepatitis C drug Sovaldi, along with a new class action lawsuit against Blue Cross Blue Shield involving Harvoni coverage, are the latest in a series of controversies surrounding the 2 drugs.